COMET: Results and implications for the treatment of heart failure
Over the course of 25 years, the use of ß-blocking agents to treat heart failure has evolved from a contraindication to an established treatment for mild-to-moderate disease.1
Three ß-blockers-bisoprolol, extended-release (ER) metoprolol succinate, and carvedilol-have been shown to produce significant reductions in mortality and morbidity in a wide range of patients with heart failure and impaired left ventricular function.2-4
The success of ß-blockers in treating heart failure has led to debate over whether the clinical benefits are strictly due to ß1-receptor blockade or if the ancillary ß2- and a1-blocking properties of nonselective agents such as carvedilol provide some additional advantage.1 To address this issue, the Carvedilol Or Metoprolol European Trial (COMET) compared the effects of carvedilol with the ß1-receptor blocker immediate-release (IR) metoprolol tartrate on the risk of death and of death and hospitalization in patients with chronic heart failure.5
In this Data Alert the findings of the COMET trial and their relevance for clinical practice are discussed.
References are listed at the end of the Data Alert.
Download 03DA_COMET.ppt (6 slides - 1.2MB)